Phase 1 Clinical Study

PharmaTher’s Sairiyo Therapeutics Inc. Advances Clinical Development of Patented Reformulated Cepharanthine for Phase 1 Study in Australia

Staff Reporter February 21, 2024 0

PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company, announced today Sairiyo Therapeutics Inc....

23andMe Announces FDA Clearance of IND Application for its Dual Mechanism Antibody, 23ME-01473, Targeting ULBP6

Staff Reporter January 31, 2024 0

23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company, announced the U.S. Food and Drug Administration...

Dr. Vivek Kumar, Senior Consulting Cosmetic & Plastic Surgeon at Sculpt Clinics, Delhi, India, smiling.

Sculpt Clinics Introduces New Laser Hair Removal Technology

Staff Reporter September 6, 2024 0

HEAL Foundation Announces Healthcare CSR Summit & Awards in New Delhi

Staff Reporter August 22, 2024 0

Apsara Ice Creams Muskaan Initiative 53rd Anniversary Celebration

Apsara Ice Creams to launch Muskaan initiative on its 53rd anniversary

Staff Reporter August 16, 2024 0

Milann Fertility Center launches 'Milann's Embrace' initiative during World Breastfeeding Week 2024.

Milann Fertility Center Celebrates World Breastfeeding Week with ‘Milann’s Embrace’ Initiative

Staff Reporter August 9, 2024 0

DCN Dx showcasing miniDxR lateral flow reader at NextGen Dx Summit 2024

DCN Dx to Showcase New Technologies at NextGen Dx 2024

Staff Reporter August 8, 2024 0

PharmaTher’s Sairiyo Therapeutics Inc. Advances Clinical Development of Patented Reformulated Cepharanthine for Phase 1 Study in Australia￼

23andMe Announces FDA Clearance of IND Application for its Dual Mechanism Antibody, 23ME-01473, Targeting ULBP6￼

Interesting Stories For You

Sculpt Clinics Introduces New Laser Hair Removal Technology

HEAL Foundation Announces Healthcare CSR Summit & Awards in New Delhi

Apsara Ice Creams to launch Muskaan initiative on its 53rd anniversary

Milann Fertility Center Celebrates World Breastfeeding Week with ‘Milann’s Embrace’ Initiative

DCN Dx to Showcase New Technologies at NextGen Dx 2024

PharmaTher’s Sairiyo Therapeutics Inc. Advances Clinical Development of Patented Reformulated Cepharanthine for Phase 1 Study in Australia

23andMe Announces FDA Clearance of IND Application for its Dual Mechanism Antibody, 23ME-01473, Targeting ULBP6